Showing 941 - 960 results of 30,980 for search '(( 5 ((wt decrease) OR (nn decrease)) ) OR ( 50 ((we decrease) OR (a decrease)) ))', query time: 0.74s Refine Results
  1. 941
  2. 942

    Neutralization of JRFL WT and mutant viruses by different MAbs and CD4-IgG2. by Chitra Upadhyay (817121)

    Published 2018
    “…A) Titration curves of representative virus-MAb pairs. B) JRFL WT and mutant neutralization by MAbs targeting V2i, V3, V2q, and the CD4bs and by CD-IgG2. …”
  3. 943
  4. 944

    Different Association of Human Papillomavirus 16 Variants with Early and Late Presentation of Cervical Cancer by Ana Alfaro (280118)

    Published 2016
    “…Interestingly, when analyzing only the HPV16-positive CC, D2 increases (OR = 2.5, 95% CI = 1.2–5, p < 0.05) and D3 decreases (OR = 0.45, 95% CI 0.2–0.9, p < 0.05) the risk to develop CC before 50 years old in relation with A1/2 variant. …”
  5. 945
  6. 946

    The <i>P[syt<sup>P-L</sup>]</i> mutation decreases the Ca<sup>2+</sup> affinity of release and vesicular release probability, but the readily releasable pool is unchanged. by Mallory C. Shields (4474210)

    Published 2017
    “…<p>(A) Mean EJP amplitudes from <i>+/-;P[syt<sup>WT</sup>]/+</i> (filled black circles) and <i>+/-;P[syt<sup>P-L</sup>]/+</i> (filled red circles) larvae at Ca<sup>2+</sup> levels ranging from 0.05 mM—5.0 mM. …”
  7. 947
  8. 948
  9. 949
  10. 950
  11. 951
  12. 952

    NatB-inactivation decreased Drk levels through its N-terminal sequences, which was regulated by the N-end rule E3 ubiquitin ligase POE/UBR4. by Zhentao Sheng (107495)

    Published 2020
    “…(C) Expression of WT Psid rescued the level of N-Drk-GFP in <i>psid-D4</i> mutant clones. …”
  13. 953
  14. 954
  15. 955

    Efficacy of Neonatal HBV Vaccination on Liver Cancer and Other Liver Diseases over 30-Year Follow-up of the Qidong Hepatitis B Intervention Study: A Cluster Randomized Controlled T... by Chunfeng Qu (114656)

    Published 2014
    “…The estimated efficacy of catch-up vaccination on HBsAg seroprevalence in early adulthood was 21% (95% CI 10%–30%), substantially weaker than that of the neonatal vaccination (72%, 95% CI 68%–75%). Receiving a booster at age 10–14 years decreased HBsAg seroprevalence if participants were born to HBsAg-positive mothers (hazard ratio [HR] = 0.68, 95% CI 0.47–0.97). …”
  16. 956
  17. 957
  18. 958
  19. 959
  20. 960